From the Research
The maximum daily dose of Tresiba (insulin degludec) is 160 units per day. Tresiba is a long-acting basal insulin that is typically administered once daily at the same time each day. The dose should be individualized based on the patient's blood glucose levels, insulin sensitivity, and response to therapy. When starting Tresiba in insulin-naïve patients with type 2 diabetes, the recommended initial dose is 10 units once daily. For patients already on insulin therapy who are switching to Tresiba, the initial dose can be determined based on the previous basal insulin dose. Dose adjustments should be made gradually, usually in increments of 2-4 units every 3-4 days, to achieve target blood glucose levels. Tresiba has a duration of action beyond 42 hours, which provides flexibility in dosing time when needed, though it's still recommended to administer at approximately the same time each day. The 160-unit maximum daily dose limit is established for safety reasons, as higher doses may increase the risk of hypoglycemia and other adverse effects.
Some key points to consider when using Tresiba include:
- Individualizing the dose based on patient factors such as blood glucose levels and insulin sensitivity 1
- Starting with a low dose and gradually increasing as needed to minimize the risk of hypoglycemia 2
- Monitoring blood glucose levels regularly to adjust the dose and prevent hypoglycemia 3
- Being aware of the potential for hypoglycemia, particularly at night, and taking steps to prevent it 4
- Considering the use of Tresiba in patients with type 2 diabetes who are prone to hypoglycemia with other insulins, as it may provide a lower risk of hypoglycemia 5
It's also important to note that the evidence supports the use of Tresiba as a safe and effective treatment for type 2 diabetes, with a lower risk of hypoglycemia compared to other insulins 1, 2, 3, 4, 5. However, the dose should always be individualized and adjusted based on patient response and blood glucose levels.